About Odyssey Therapeutics
Odyssey Therapeutics is a private company based in Boston, Massachusetts, incorporated in 2021 in Delaware. It has reported $499,245,133 raised in three offerings on Form D since October 2022. Its chief executive is Gary Glick.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jun 16, 2025 | Dec 4, 2025 | $214,025,200fully sold | 55 | $3.8M | Equity, OptionsRule 506(b) | Form D ↗ |
| Oct 25, 2023 | Dec 15, 2023amended Aug 14, 2024 | $117,210,000of $121.0M target | 43 | $2.7M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| May 13, 2022 | Oct 27, 2022 | $168,009,933of $174.9M target | 34 | $4.9M | EquityRule 506(b) | Form D ↗ |
| Total, three offerings | $499,245,133 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Odyssey Therapeutics's Form D filed Dec 4, 2025.
VO
CG
Carl Gordon
Director
CN
Carolyn Ng
Director
GG
Gary Glick
President & CEO, director
TW
Timothy Walbert
Director
Paulina Hill
Director
Also a director at Avilar Therapeutics and a board member at NextPoint Therapeutics.
NL
Nan Li
Director
JL
Jeffrey Leiden
Director
JH
Jason Haas
CFO
NT
Nia Tatsis
Director
KP
Ksenija Pavletic
Director
SC
LS
Lan Smith
Director
JC
Jill Carroll
Director
Earlier filings also listed Lorence Kim (director, last listed Aug 2024), Ian Smith (director, last listed Aug 2024), Charles Baum (director, last listed Aug 2024) and Chuck Baum (director, last listed Oct 2021).